141 related articles for article (PubMed ID: 38477858)
1. Prevalence, trends, and characteristics of metabolic dysfunction-associated steatotic liver disease among the US population aged 12-79 years.
Shen TH; Wu CH; Lee YW; Chang CC
Eur J Gastroenterol Hepatol; 2024 May; 36(5):636-645. PubMed ID: 38477858
[TBL] [Abstract][Full Text] [Related]
2. Food Insecurity, Low Household Income, and Low Education Level Increase the Risk of Having Metabolic Dysfunction-Associated Fatty Liver Disease Among Adolescents in the United States.
Paik JM; Duong S; Zelber-Sagi S; Lazarus JV; Henry L; Younossi ZM
Am J Gastroenterol; 2024 Jun; 119(6):1089-1101. PubMed ID: 38477467
[TBL] [Abstract][Full Text] [Related]
3. The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Elsaid MI; Bridges JFP; Mumtaz K; Li N; Sobotka L; Rustgi VK; Paskett ED
PLoS One; 2024; 19(3):e0299836. PubMed ID: 38489287
[TBL] [Abstract][Full Text] [Related]
4. Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018.
Tan Z; Wu Y; Meng Y; Liu C; Deng B; Zhen J; Dong W
Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068789
[TBL] [Abstract][Full Text] [Related]
5. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
6. The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults.
Perumpail BJ; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A; Kim D
J Pediatr Gastroenterol Nutr; 2024 Apr; ():. PubMed ID: 38623942
[TBL] [Abstract][Full Text] [Related]
7. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
Ochoa-Allemant P; Marrero JA; Serper M
Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in south Central Uganda: A cross-sectional survey.
Enriquez R; Homsi M; Ssekubugu R; Nabukalu D; Zeebari Z; Marrone G; Gigante B; Chang LW; Reynolds SJ; Nalugoda F; Ekström AM; Hagström H; Nordenstedt H
Aliment Pharmacol Ther; 2024 May; 59(9):1111-1121. PubMed ID: 38459720
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies.
van Son KC; Te Nijenhuis-Noort LC; Boone SC; Mook-Kanamori DO; Holleboom AG; Roos PR; Lamb HJ; Alblas G; Coenraad MJ; Rosendaal FR; de Mutsert R; Tushuizen ME
Medicine (Baltimore); 2024 Jan; 103(1):e34934. PubMed ID: 38181294
[TBL] [Abstract][Full Text] [Related]
10. Alanine aminotransferase cutoffs for the pediatric fatty liver disease: Major impact of the reference population.
Aitokari L; Lahti S; Kivelä L; Riekki H; Hiltunen P; Vuorela N; Viitasalo A; Soininen S; Huhtala H; Lakka T; Kurppa K
J Pediatr Gastroenterol Nutr; 2024 Mar; 78(3):488-496. PubMed ID: 38314943
[TBL] [Abstract][Full Text] [Related]
11. Association between food insecurity and metabolic dysfunction-associated steatotic liver disease/significant fibrosis measured by fibroscan.
Kim D; Perumpail BJ; Cholankeril G; Ahmed A
Eur J Nutr; 2024 Apr; 63(3):995-1001. PubMed ID: 38260997
[TBL] [Abstract][Full Text] [Related]
12. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
Clayton-Chubb D; Kemp WW; Majeed A; Lubel JS; Woods RL; Tran C; Ryan J; Hodge A; Schneider HG; McNeil JJ; Roberts SK
Liver Int; 2024 Jan; 44(1):39-51. PubMed ID: 37698034
[TBL] [Abstract][Full Text] [Related]
13. Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database.
Nemer M; Osman F; Said A
Ann Hepatol; 2024; 29(3):101491. PubMed ID: 38412922
[TBL] [Abstract][Full Text] [Related]
14. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
15. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.
Song R; Li Z; Zhang Y; Tan J; Chen Z
Liver Int; 2024 Apr; 44(4):1051-1060. PubMed ID: 38293788
[TBL] [Abstract][Full Text] [Related]
16. Association between the skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease: A cross-sectional study of NHANES 2017-2018.
Mai Z; Chen Y; Mao H; Wang L
J Diabetes; 2024 Jun; 16(6):e13569. PubMed ID: 38751375
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic Phenotype of Hepatic Steatosis and Fibrosis in Mexican Children Living with Obesity.
Garibay-Nieto N; Pedraza-Escudero K; Omaña-Guzmán I; Garcés-Hernández MJ; Villanueva-Ortega E; Flores-Torres M; Pérez-Hernández JL; León-Hernández M; Laresgoiti-Servitje E; Palacios-González B; López-Alvarenga JC; Lisker-Melman M; Vadillo-Ortega F
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893503
[No Abstract] [Full Text] [Related]
18. Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men.
Crudele L; De Matteis C; Novielli F; Di Buduo E; Petruzzelli S; De Giorgi A; Antonica G; Berardi E; Moschetta A
Biol Sex Differ; 2024 May; 15(1):43. PubMed ID: 38760802
[TBL] [Abstract][Full Text] [Related]
19. Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study.
Taniguchi H; Ueda M; Sano F; Kobayashi Y; Shima T
JGH Open; 2024 May; 8(5):e13082. PubMed ID: 38779132
[TBL] [Abstract][Full Text] [Related]
20. Poorly controlled pediatric type 1 diabetes mellitus is a risk factor for metabolic dysfunction associated steatotic liver disease (MASLD): An observational study.
Koutny F; Wiemann D; Eckert A; Meyhöfer S; Fritsch M; Pappa A; Wiegand S; Weyer M; Wurm M; Weghuber D; Holl RW
J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1027-1037. PubMed ID: 38558281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
